title: Microinjection of adenosine into the hypothalamic ventrolateral preoptic area enhances wakefulness via the A1 receptor in rats.
abstract: Adenosine (AD) is a nucleic acid component that is critical for energy metabolism in the body. AD modulates numerous neural functions in the central nervous system, including the sleep-wake cycle. Previous studies have indicated that the A1 receptor (A1R) or A2A receptor (A2AR) may mediate the effects of AD on the sleep-wake cycle. The hypothalamic ventrolateral preoptic area (VLPO) initiates and maintains normal sleep. Histological studies have shown A1R are widely expressed in brain tissue, whereas A2AR expression is limited in the brain and undetectable in the VLPO. We hypothesize therefore, that AD modulates the sleep-wake cycle through A1R in the VLPO. In the present study, bilateral microinjection of AD or an AD transporter inhibitor (s-(4-nitrobenzyl)-6-thioinosine) into the VLPO of rats decreased non-rapid eye movement (NREM) and rapid eye movement (REM) sleep. An A1R agonist (N6-cyclohexyladenosine) produced similar effects in the VLPO. Microinjection of an A1R antagonist (8-cyclopentyl-1,3-dimethylxanthine) into the VLPO enhanced NREM sleep and diminished AD-induced wakefulness. These data indicate that AD enhances wakefulness in the VLPO via A1R in rats.
authors: Department of Neurology, The First Hospital of Anhui Medical University, Hefei, Anhui Province, People's Republic of China.
authors: Jin
authors: J
authors: Zhang
authors: Dou
authors: D
authors: Yin
authors: Fang
authors: F
authors: Wu
authors: Gongliang
authors: G
authors: Zhang
authors: Chuanwei
authors: C
authors: Jiang
authors: Zhen
authors: Z
authors: Li
authors: Liecheng
authors: L
authors: Wang
authors: Kai
authors: K
authors: Wang
mesh_terms: D000241:Adenosine / Q000008:administration & dosage* / Q000494:pharmacology; D000818:Animals; D008297:Male; D008845:Microinjections; D011301:Preoptic Area / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D043682:Receptor, Adenosine A1 / Q000502:physiology*; D014851:Wakefulness / Q000187:drug effects*
chemical_list: D043682:Receptor, Adenosine A1; D000241:Adenosine
references: Pharmacol Rev. 2001 Dec;53(4):527-52
references: 11734617
references: Science. 1997 May 23;276(5316):1265-8
references: 9157887
references: J Cell Physiol. 2005 Jan;202(1):9-20
references: 15389588
references: Brain Res. 2004 Dec 3;1028(2):225-32
references: 15527748
references: Br J Pharmacol. 1996 Jul;118(6):1461-8
references: 8832073
references: Neuroscience. 2003;116(3):913-20
references: 12573729
references: Brain Res. 1998 Aug 24;803(1-2):178-88
references: 9729371
references: Behav Brain Res. 2000 Nov;115(2):183-204
references: 11000420
references: Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5980-4
references: 8650205
references: Nat Neurosci. 2005 Jul;8(7):858-9
references: 15965471
references: Neuroscience. 2008 Jun 2;153(4):875-80
references: 18440150
references: Mol Endocrinol. 1991 Aug;5(8):1037-48
references: 1658635
references: Curr Top Med Chem. 2011;11(8):1047-57
references: 21401496
references: Brain Res. 2009 Dec 22;1304:96-104
references: 19781535
references: J Pharmacol Exp Ther. 1984 Feb;228(2):268-74
references: 6694111
references: Neuroscience. 2004;123(2):451-7
references: 14698752
references: Neuroscience. 2000;99(3):507-17
references: 11029542
references: J Neurosci. 1998 Jun 15;18(12):4705-21
references: 9614245
references: Neuroscience. 1997 Jul;79(1):225-35
references: 9178878
references: J Comp Neurol. 2006 Feb 10;494(5):845-61
references: 16374809
references: J Physiol. 2004 May 1;556(Pt 3):935-46
references: 14966298
references: Pharmacol Rev. 1998 Sep;50(3):413-92
references: 9755289
references: J Comp Neurol. 1998 Nov 16;401(2):163-86
references: 9822147
references: Eur J Pharmacol. 1996 Apr 11;300(3):163-71
references: 8739204
references: Eur J Neurosci. 1999 May;11(5):1587-97
references: 10215911
references: Brain Res. 2000 Jan 10;852(2):479-81
references: 10678777
references: Neuroscience. 2005;134(4):1377-90
references: 16039802
references: Am J Physiol Regul Integr Comp Physiol. 2005 Dec;289(6):R1715-23
references: 16109808
references: Neuroscience. 1996 Jul;73(1):99-107
references: 8783234
references: Am J Physiol Regul Integr Comp Physiol. 2000 Dec;279(6):R2079-88
references: 11080072
references: J Neurosci. 2000 May 15;20(10):3830-42
references: 10804223
references: J Comp Neurol. 2001 Jan 22;429(4):638-53
references: 11135241
references: Neuroscience. 2003;119(4):913-8
references: 12831851
references: Neuroscience. 2003;122(4):1107-13
references: 14643776
references: Brain Res. 1987 Feb 10;403(1):177-80
references: 3828812
references: Neurology. 2003 Dec 9;61(11 Suppl 6):S94-6
references: 14663019
references: J Neurophysiol. 1995 Nov;74(5):2150-62
references: 8592203
references: Neuropsychopharmacology. 1990 Aug;3(4):243-9
references: 2400543
references: Science. 1996 Jan 12;271(5246):216-9
references: 8539624
references: Brain Res. 1995 Apr 24;677(2):193-203
references: 7552243
references: J Neurosci. 2007 Feb 28;27(9):2410-5
references: 17329439
references: J Neurochem. 2006 Mar;96(6):1750-9
references: 16539690
references: J Physiol. 1954 Jan;123(1):148-67
references: 13131253